Selonterra and Axxam Enter into Drug Discovery Collaboration

June 16, 2020

San Mateo, California (USA) and Milan, Italy – Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading discovery research company, announce a collaboration for the identification of novel small molecule therapies for Alzheimer’s disease (AD), based on Selonterra’s proprietary APOE4 mechanism.

Through this collaboration, Selonterra will have access to Axxam’s expertise in discovery biology, in particular functional assays, and to its highly diverse and novel small molecule compound collection with the aim of developing small molecules acting on unexploited and highly druggable AD targets identified by Selonterra.

Open PDF document